Abstract：
The gut microbiome has been recognised as a key component in the pathogenesis of inflammatory bowel diseases (IBD), and the wide range of metabolites produced by gut bacteria are an important mechanism by which the human microbiome interacts with host immunity or host metabolism. High-throughput metabolomic profiling and novel computational approaches now allow for comprehensive assessment of thousands of metabolites in diverse biomaterials, including faecal samples. Several groups of metabolites, including short-chain fatty acids, tryptophan metabolites and bile acids, have been associated with IBD. In this Recent Advances article, we describe the contribution of metabolomics research to the field of IBD, with a focus on faecal metabolomics. We discuss the latest findings on the significance of these metabolites for IBD prognosis and therapeutic interventions and offer insights into the future directions of metabolomics research.
摘要：
肠道微生物组已被认为是炎症性肠病（IBD）发病机理的关键组成部分，肠道细菌产生的广泛代谢产物是人类微生物组与宿主免疫或宿主代谢相互作用的重要机制。高通量代谢组学分析和新的计算方法现在允许对不同生物材料中的数千种代谢物进行全面评估。包括粪便样本.几组代谢物，包括短链脂肪酸,色氨酸代谢物和胆汁酸，与IBD有关。在这篇最新进展文章中，我们描述了代谢组学研究对IBD领域的贡献，重点是粪便代谢组学。我们讨论了这些代谢物对IBD预后和治疗干预的重要性的最新发现，并为代谢组学研究的未来方向提供了见解。
